- BEST B-SCHOOLS
- INDIA'S BEST EMPLOYERS
- HOTTEST YOUNG EXECUTIVES
- TOP EMERGING COMPANIES
- BEST CFOs
- BEST BANKS
- COOLEST START-UPS
- BEST INNOVATIONS
- MOST POWERFUL BUSINESSWOMEN
- WOMEN'S ISSUE
- BEST SMEs
- LUXURY SPECIAL
- BEST CEOs
- ANNIVERSARY SPECIAL
- UNION BUDGET
- BUSINESS TODAY
- BT MORE
- MONEY TODAY
- GADGETS AND GIZMOS
The company said the approval by the US FDA for Raloxifene Hydrochloride tablets is for strength of 60 mg, which is bio and therapeutically equivalent to the reference listed drug product (RLD) Evista, 60 mg of Eli Lilly.
Under the service, people can visit Common Service Centres (CSC) and fix an appointment for seeking expert consultancy with a doctor.
All the drugs being recalled by the company have been manufactured at its Mumbai-based facility and distributed in the US by its subsidiary, Wockhardt USA
The Indian drug firms have joined the global fight against antibiotic-resistant bacteria. The good news is that they are steadily moving ahead.
The firm's research arm - Sun Pharma Advanced Research Company - is currently working on three new drugs that are currently under clinical trial stage.
News You Can Use
- Last day for filing I-T returns today: Your checklist
- Now, 55,000 buyers can occupy their Noida flats soon
- Vistara enters fare war, offers free ticket with every purchase
- Bharti Airtel slashes broadband plan prices by 30%
- China devalues yuan: All you need to know
- Yamaha launches sports bike 'YZF-R3' at Rs 3.25 lakh